Non Small Cell Lung Cancer Treatment

Bayer Lung Cancer Drug Lands Speedy FDA Nod

US FDA approves Bayer drug for specific type of lung cancer

The U.S. Food and Drug Administration said on Wednesday that it has approved Bayer's drug for patients with a form of lung cancer that has advanced or spread despite earlier treatments. The drug, branded as Hyrnuo,

BioSpace · 16h

Bayer Wins Lung Cancer Accelerated Approval for Kinase Inhibitor

Fierce Pharma · 1d

Bayer edges onto Boehringer's turf with FDA nod for HER2-mutated lung cancer med Hyrnuo

MedCity News

Bayer Lung Cancer Drug Lands Speedy FDA Nod to Stay Competitive With a Boehringer Ingelheim Med

The accelerated FDA approval of Bayer's Hyrnuo covers treatment of advanced cases of non-small cell lung cancer with HER2 ...

European Medical Journal

New NCCN Guidelines Add Treatment Options for NSCLC

New NSCLC guideline updates outline expanded perioperative immunotherapy, adjuvant targeted therapy, and consolidation ...

CURE

Understanding Emerging Cell Therapy in Lung Cancer

Cellular therapies, including TIL, TCR, and CAR-T, are transforming lung cancer care by utilizing personalized immune cells ...

Ankyra Therapeutics Announces First Patient Dosed in Phase 1b Trial Evaluating First-in-Class Anchored Immunotherapy in Combination with Immune Checkpoint Blockade in Patients ...

Ankyra Therapeutics, a clinical-stage biotechnology company pioneering anchored drug conjugate technology for cancer and other diseases, today announced that the first patient has been dosed in its ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results